Contents
Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.
Visit our Writing Guide or this topic page for additional help.
Timeline
August 10, 2019
ORIC Pharmaceuticals raises a $55,000,000 series D round from ArrowMark Partners.
August 9, 2019
ORIC Pharmaceuticals raises a $55,000,000 series D round from ArrowMark Partners, Casdin Capital, City Hill Ventures, Correlation Ventures, EcoR1 Capital, Foresite Capital, Hartford Healthcare Endowment, Invus, Irving Capital, Memorial Sloan Kettering Cancer Center, OrbiMed, Taiho Ventures LLC, The Column Group and Topspin Partners.
February 21, 2018
ORIC Pharmaceuticals raises a $50,000,000 series C round from EcoR1 Capital, Foresite Capital, Memorial Sloan Kettering Cancer Center, OrbiMed, Taiho Ventures LLC and The Column Group.
Funding Rounds
Open in Query Tool
Products
Open in Query Tool
Acquisitions
Open in Query Tool
SBIR/STTR Awards
Open in Query Tool
Patents
Open in Query Tool
Further Resources
Title
Author
Link
Type
Date
References
Company attributes
Pitchbook URL
Legal Name
ORIC Pharmaceuticals, Inc.
Number of Employees (Ranges)
50 – 99
Number of Employees
79
Full Address
240 East Grand Avenue 2nd Floor South San Francisco, CA 94080 United States
12265 El Camino Real Suite 370 San Diego, CA 92130
CIK Number
Place of Incorporation
Investors
IRS Number
471,787,157
Founded Date
2014
Email Address
info@oricpharma.com
Phone Number
+16503885600
Total Funding Amount (USD)
160,000,000
Latest Funding Round Date
August 10, 2019
Stock Symbol
ORIC
Exchange
Board of Directors
Latest Funding Type
NAICS Code
325,412
Patents Assigned (Count)
9
Other attributes
Country
Company Operating Status
Active
Ticker Symbol
ORIC
Latest Funding Round Amount (USD)
55,000,000
Headquarters
SIC Code
2,834
